Other

Smithkline Beecham Corporation

Shionogi Company Limited

Glaxosmithkline LLC

Viiv Healthcare Company

Eric Eugene Boros

Roy A Swaringen, Jr

Robert Anthony Mook

Eric C Bigham

John J Savarese

Grady Evan Boswell

Sanjay Shashikant Patel

James Benjamin Thompson

Cecilia Suarez Koble

Vincente Samano

Brian Alvin Johns

Wieslaw Mieczyslaw Kazmierski

Michael H Rabinowitz

Jason Gordon Weatherhead

Philip Stewart Turnbull

Noriyuki Kurose

Ronald George Sherrill

David John Cowan

Maosheng Duan

Dennis Heyer

Subba Reddy Katamreddy

Jeffrey Alan Oplinger

Pek Yoke Chong

Hitoshi Murai

Anthony Louis Handlon

Andrew J Carpenter

Jennifer Poole Peckham

Christopher R Conlee

Richard Dama Caldwell

Clifton Earl Hyman

Brian D Thompson

Felix Deanda, Jr

Neil Bifulco, Jr

Ed Williams McLean

Takshi Kawasuji

Chrisopher Joseph Aquino

Brian Andrew Chauder

Angilique C Perkins

Dana Vanderwall

Ashok Bhandari

The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

Chemical compounds

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

CCR5 antagonists as therapeutic agents

The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions.

Condensed heterocyclic compounds as calcitonin agonists

Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z,and Z,are methyl; W,and W,are carbon; and A is a pharmaceutically acceptable anion.

Substituted isoquinolines as ultra short acting neuromuscular blockers

Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X,and X,are independently halogen; h,and h,are independenity from 0 to 2; Z,and Z,are indepentdently hydrogen, C,alkyl, C,alkenyl or C,alkynyl with the proviso that Z,and Z,are not both hydrogen; Y,, Y,, and Y,and Y,are independently hydrogen, halogen or C,alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if h,and h,are both 0, then r is 0 and n is 0 to 2; R,to R,are independently hydrogen, halogen, C,alkoxy, or R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, may independently form a methylenedioxy or ethylenedioxy moiety contained in five- or six-membered ring; W,and W,are carbon; and A is a pharmaceutically acceptable anion.

Growing community of inventors

Durham, NC, United States of America

Eric Eugene Boros